VTV THERAPEUTICS
vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. vTv Therapeutics has a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, in... flammation, and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality and breadth of vTv's product candidate pipeline, platform technology, scientific team, and strategic collaborations have enabled it to become a fully integrated pharmaceutical company. The company's commitment to drug discovery is reflected in its medical solutions and the many exciting potential new treatment options in its pipeline. The company's major R&D activities have focused on central nervous system disorders, metabolic disorders, inflammation and oncology. vTv Therapeutics is advancing several proprietary drug candidates. The company's lead candidate, azeliragon (aka TTP488), is a novel, orally bioavailable small molecule compound that is being developed for the treatment of Alzheimer's disease. In Phase 2 clinical trial in patients with mild to moderate Alzheimer's disease, azeliragon showed a statistically significant difference of more than 3 points in ADAS-cog at 18 months compared to placebo. Azeliragon has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). The Phase 3 study in patients with mild Alzheimer's disease was initiated in April 2015 with a clear path forward to registration with the aim to demonstrate disease modification. vTv Therapeutics is also prosecuting the clinical development of TTP399, a novel functionally liver-selective Glucokinase Activator ("GKA") for the treatment of type 2 diabetes. In a Phase 2a study, TTP399 normalized patients' HbA1c without inducing hypoglycemia, after only six weeks of treatment. A six-month Phase 2 study is ongoing.
VTV THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Innovation Management Pharmaceutical
Founded:
1998-01-01
Address:
High Point, North Carolina, United States
Country:
United States
Website Url:
http://www.vtvtherapeutics.com
Total Employee:
251+
Status:
Active
Contact:
+3368410300100
Email Addresses:
[email protected]
Total Funding:
41 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical companyย focused on theย prevention and treatment of gastrointestinal disorders.
Sorrento Therapeutics
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
Current Advisors List
Current Employees Featured
Stock Details
Investors List
CinPax
CinPax investment in Post-IPO Equity - vTv Therapeutics
G42 Healthcare
G42 Healthcare investment in Post-IPO Equity - vTv Therapeutics
Key Employee Changes
Date | New article |
---|---|
2022-07-27 | vTv Therapeutics appoints Paul Sehkri as new president and CEO |
2022-03-04 | vTv Therapeutics Announces CEO Transition |
2021-10-20 | vTv Therapeutics Announces Deepa Prasad as New President and CEO |
Official Site Inspections
http://www.vtvtherapeutics.com Semrush global rank: 3.4 M Semrush visits lastest month: 4.6 K
- Host name: cloudhost-1964024.us-midwest-1.nxcli.net
- IP address: 104.207.254.13
- Location: Southfield United States
- Latitude: 42.4593
- Longitude: -83.2207
- Metro Code: 505
- Timezone: America/Detroit
- Postal: 48075